



Association between Common Genetic Variants and Polycystic Ovary Syndrome Risk in a Chinese Han Population

Ying Sun¹, Yi Yuan², Hua Yang³, Jingjie Li³, Tian Feng³, Yongri Ouyang³, Tianbo Jin³, Ming Liu⁴

¹*Xi'an Jiaotong University School of Medicine, Department of Pathology, Xi'an, China*

²*Han Zhong Central Hospital, Clinic of Obstetrics and Gynecology, Han Zhong, China*

³*Northwest University School of Life Sciences, Xi'an, China*

⁴*Xi'an Jiaotong University Second Affiliated Hospital, Department of Obstetrics and Gynecology, Xi'an, China*

ABSTRACT

Objective: Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5-7% of reproductive age women worldwide. The aim of our study was to explore the PCOS-related single nucleotide polymorphism (SNP) associations between common genetic variants and PCOS risk in a Han Chinese women population.

Methods: In this case-control study, 285 Chinese Han women aged 28.50±6.858 years with PCOS and 299 controls of a mean age of 32.66±7.018 years were compared. We selected recently published genome-wide association studies (GWAS) which identified several genetic loci in PCOS. All the SNPs were genotyped by Sequenom Mass-ARRAY technology. Associations between the gene and the risk of PCOS were tested using various genetic models by Statistical Package for the Social Sciences and Plink.

Results: We found that rs705702 in the *RAB5B/SUOX* was associated with PCOS (odds ratio=1.42; 95% confidence interval=1.08-1.87, p=0.011) and increased the PCOS risk. The genotypic model analysis also showed that rs705702 was associated with PCOS risk.

Conclusion: Our results suggest that SNPs rs705702 in gene *RAB5B/SUOX* was associated with PCOS in Han Chinese women.

Keywords: Polycystic ovary syndrome, single nucleotide polymorphism, Chinese Han women

Conflict of interest: None declared

Received: 28.12.2015

Accepted: 22.05.2016

WHAT IS ALREADY KNOWN ON THIS TOPIC?

The first genome-wide association studies and subsequent follow-up performed on Han Chinese populations identified the following Polycystic ovary syndrome (PCOS) candidate loci: *DENND1A*, *INSR*, *YAP1*, *C9orf3*, *RAB5B*, *HMGGA2*, *TOX3*, *SUMO1P1/ZNF217*, *THADA*, follicle-stimulating hormone receptor; luteinizing hormone/choriogonadotropin receptor.

WHAT THIS STUDY ADDS?

Single nucleotide polymorphisms rs705702 in gene *RAB5B/SUOX* was associated with PCOS in Han Chinese women.

Introduction

Polycystic ovary syndrome (PCOS) is the most common reproductive disorder in women. It is a complex, heterogeneous disorder characterized by chronic anovulation, clinical and/or

Address for Correspondence

Tianbo Jin MD, Northwest University School of Life Sciences, Xi'an, China

Phone: +86-29-88302831 E-mail: tianbojin1973@163.com

©Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing.

biochemical hyperandrogenism and polycystic ovaries. It is the most common endocrine disorder in premenopausal women and affects up to 10% of them (1). The pathogenesis of PCOS is not fully understood, but it is accepted as a multifactorial disorder that arises from interactions between genetic, environmental, and intrauterine factors (2,3). Several family and twin studies indicate a strong genetic basis and twin studies of heredity provide the most rigorous demonstration that the disorder has a genetic component. Twin studies have provided heritability estimates for PCOS of 70% (4). Several groups have undertaken genetic studies to identify the etiology of PCOS. Genome-wide association studies (GWAS) offer a potentially powerful approach to identify the associations between millions of single-nucleotide polymorphisms (SNPs) and specific traits or disorders (5). The first GWAS and subsequent follow-up performed on Han Chinese populations identified the following PCOS candidate loci: *DENND1A*, *INSR*, *YAP1*, *C9orf3*, *RAB5B*, *HMG2*, *TOX3*, *SUMO1P1/ZNF217*, *THADA*, follicle-stimulating hormone receptor (FSHR), luteinizing hormone/choriogonadotropin receptor (LHCGR) (6,7). At 19p13.3, rs2059807 is located in the intron of the *INSR* (insulin receptor) gene and in previous studies, common SNPs in the *INSR* gene have been reported to be associated with PCOS in both Han Chinese individuals and those of European ancestry. *INSR* has an important role in insulin metabolism, consistent with a very common explanation for the pathogenesis of PCOS, namely, insulin resistance (8). Mutations affecting the tyrosine kinase domain of the insulin receptor are known to cause severe hyperinsulinemia and insulin resistance (9). LHCGR is expressed on the surface of target cells of reproductive organs such as the ovary, uterus, fallopian tube, and in a variety of other tissues including vascular endothelium (10,11). Studies conducted over the past decade have built a convincing argument that genetic factors contribute to development of PCOS. Despite advances in genetic technologies, very few PCOS susceptibility genes have been validated. To date, there are only a few published genome-wide associated variants for PCOS in Han Chinese women. Indeed, these studies will be important because the susceptibility variants may differ in individual ethnic groups as do the phenotypic features of PCOS. It has been well established that ethnic background adds to the phenotypic diversities in PCOS patients. Although one group recently replicated two of these loci (12), another did not (13). We examined the same susceptibility variants in additional PCOS case-control sets in Han Chinese women. We also investigated variants that correlate strongly with the risk variants in the Chinese population for association with PCOS in the case-control study.

Methods

In this case-control study, 584 women were recruited from the Second Affiliated Hospital, Xi'an Jiatong University, during 2009 to 2013. Among these subjects who were all Han

Chinese women, 285 were diagnosed as PCOS according to the National Institutes of Health criteria (14). The mean age of this study group was 28.50 ± 6.858 years. None of the subjects had any other diseases and none of them had undergone chemotherapy or radiotherapy. All were unrelated individuals of reproductive age who had received no hormonal therapy for at least three months prior to the study. The control group consisted of 299 healthy women of a mean age of 32.66 ± 7.018 years.

The study was approved by the ethics committee of the Second Affiliated Hospital, Xi'an Jiatong University, and written informed consent was obtained from all participants.

Weight and height were measured in all subjects by standard protocol and calibrated instruments. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m^2). Demographic and personal data were collected through a face to face interview using a standardized epidemiological questionnaire, including age, ethnicity, residential region, and family history of PCOS. In addition, relevant information for PCOS patients was collected through consultation with treating physicians or through a review of the medical chart.

A peripheral blood sample of 5 mL was taken from all participants.

Single-Nucleotide Polymorphism Selection and Genotyping

From the previously published work, we selected 10 SNPs which could be associated with PCOS. Additionally, minor allele frequency (MAF) of these SNPs in the HapMap CHB (Chinese Han Beijing) population was $>5\%$. We used the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd. Xi'an City, China) for the extraction of genomic DNA from whole blood, and DNA concentration was measured by NanoDrop 2000 (Gene Company Limited). We used Sequenom MassARRAY Assay Design 3.0 Software to design Multiplexed SNP MassEXTEND assay (15). We performed Sequenom MassARRAY RS1000 to genotype the SNPs using the standard protocol recommended by the manufacturer (15). Finally, data management and analysis were performed by Sequenom Typer 4.0 Software (15,16). Laboratory personnel were blinded to the genotyping results of all samples.

Statistical Analysis

Microsoft Excel and Statistical Package for the Social Sciences 19.0 statistical package (SPSS, Chicago, IL, USA) were used to perform the statistical analyses. A p -value <0.05 was considered statistically significant. The validation of each SNP frequency in control subjects was tested for departure from Hardy-Weinberg Equilibrium (HWE) using an exact test. The χ^2 test was used to compare the distribution of genotypes and allele frequencies between patients and control subjects. The most common genotype in the controls was used as reference group. The associations between the genes and the risk of PCOS were tested using genetic models (co-dominant, dominant, recessive, over-dominant, and log-additive) analysis

by SNP stats, website software from <http://bioinfo.iconcolgia.net/snpstats/start.htm>. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression analysis adjusted for age and gender (17). We used the Haploview software package (version 4.2) and SHEsis software platform (<http://www.nhgg.org/analysis/>) for analyses of linkage disequilibrium (LD), haplotype construction, and genetic association at polymorphism loci, and $D' > 0.8$ indicated that the related tSNPs formed one block (18,19).

Results

The characteristics of PCOS and control subjects are presented in Table 1. The PCOS group was older than the control group ($p < 0.001$). There were no significant differences in BMI ($p = 0.585$). As listed in Table 2, a multiplexed SNP MassEXTEND assay was designed with the Sequenom MassARRAY Assay Design 3.0 Software. No significant deviation of allele frequencies from HWE was found in PCOS and control groups. We investigated the possibility of the minor allele of each SNP being a risk factor compared

with the wild-type allele. As shown in Table 3, the allele and genotype frequencies of the ten SNP were not significantly different between PCOS patients and healthy controls. As shown in Table 3, we found that rs705702 in the *SUOX* was associated with PCOS (OR=1.42; 95% CI=1.08-1.87, $p = 0.011$) and increased the PCOS risk. The genotypic model analysis showed that rs705702 was associated with PCOS risk (Table 4) and logistic regression analysis adjusted for age and BMI also showed an association with PCOS risk. Using the AA genotypes combined as a reference, the AG/GG genotype of rs705702 was significantly associated with an increased risk of PCOS (adjusted $p = 0.018$, OR=1.52; 95% CI=1.07-2.16, Dominant model). In the log additive model, we found that rs705702 was significantly associated with an increased risk of PCOS (adjusted $p = 0.014$, OR=1.42; 95% CI=1.07-1.98). Since the pattern of LD is highly structured into conserved blocks of sequence separated by hotspots of recombination, the final function of a conserved haplotype may be the result of interaction among polymorphisms within the block. We analyzed linkage LDs among the SNPs and these SNPs showed no tight links.

Discussion

In this case-control study, we aimed to determine whether variants recently identified in a GWAS for PCOS in Chinese Han subjects would be associated with PCOS in Xi'an Chinese Han people. This is the first study to report the frequencies of genotypes and alleles in ten different SNPs (rs13405728, rs3802457, rs1894116, rs705702, rs2272046, rs1961177, rs1048943, rs4784165, rs2059807, rs6022786), which were identified by GWAS, between PCOS and healthy Xi'an Han

Table 1. Clinical characteristics of the Polycystic ovary syndrome cases and of the control group

	Age (years)		BMI (kg/m ²)	
	Cases	Controls	Cases	Controls
n	285	299	285	299
Mean ± SD	28.5±6.858	32.66±7.018	20.49±2.713	20.61±2.801
p-value	< 0.001		0.585	

SD: standard deviation, BMI: body mass index
p-value ≤0.05 indicates statistical significance

Table 2. Polymerase chain reaction primers

SNP ID	1 st -PCR primer sequences	2 nd -PCR primer sequences	UEP sequences
rs13405728	ACGTTGGATGCTTCAATATCCTGGGCTTAC	ACGTTGGATGGATTAGAAAACCTGCTCTGG	gCACCATAATGCAGCCATTTGT
rs3802457	ACGTTGGATGGTTGGGAAAGCCAGTTTCGG	ACGTTGGATGTTCACTACTCTCCAGGAAGC	GGAGGATAAGGCATATTCAT
rs1894116	ACGTTGGATGAAATTTAGTTGCATTGAGG	ACGTTGGATGAAGGATTGACCAGTCAAG	CTACATAATATTGATTCTAGACAATT
rs705702	ACGTTGGATGACGAGAACTAAGCGATTGAC	ACGTTGGATGCCACTTTAAACCCAGGGTAG	GTAGTTGTAGTTGCAACAG
rs2272046	ACGTTGGATGGGATTCAGTAATTGGCCTTG	ACGTTGGATGACATTCTGCATGCATTGTCC	cTGGCCTTGGGACATTTG
rs6022786	ACGTTGGATGTTTAAACCCCTCAGTTTCTC	ACGTTGGATGCCTAGAGAAATTGCTTAGAC	GACTATTTAGCTGGTGAC
rs2059807	ACGTTGGATGATGTGAATCAGACCTCTTGC	ACGTTGGATGAGCCAATAACCATATCAAGG	TCAGACCTCTTCTTTAA
rs4784165	ACGTTGGATGACTGATCCTCTGCCTACTTC	ACGTTGGATGCCAGCCGTACATAATCCAC	TTTCCCTATTAAGAACATCC
rs1048943	ACGTTGGATGTGGGCAAGCGGAAGTGATC	ACGTTGGATGCTGAATTCCACCCGTTGCAG	gagctGAAGTGATCGGTGAGACC
rs1961177	ACGTTGGATGAAATTCAGAAGTCTAAGG	ACGTTGGATGCTCCCTATAAGTCACTTG	aagAAGGATGAAAAGAAAATCTTACA

PCR: polymerase chain reaction, SNP: single-nucleotide polymorphism, UEP: unique-event polymorphism

Table 3. Basic information of candidate single-nucleotide polymorphisms in this study

SNP ID	Chromosome	Alleles A/B	Gene	MAF		p-HWE	OR (95% CI)	p-value
				Cases	Controls			
rs13405728	2p16.3	G/A	<i>LHCGR</i>	0.221	0.232	0.002	0.94 (0.71-1.23)	0.642
rs3802457	9q22.32	A/G	<i>C9orf3</i>	0.133	0.167	0.409	0.77 (0.55-1.06)	0.106
rs1894116	11q22.1	G/A	<i>YAP1</i>	0.256	0.219	0.612	1.23 (0.94-1.61)	0.136
rs705702	12q13.2	G/A	<i>SUOX</i>	0.261	0.199	0.467	1.42 (1.08-1.87)	0.011
rs2272046	12q14.3	C/A	<i>HMGA2</i>	0.075	0.084	0.706	0.89 (0.58-1.37)	0.606
rs1961177	15q21.2	T/C	<i>GLDN</i>	0.190	0.159	0.665	1.23 (0.91-1.67)	0.174
rs1048943	15q24.1	C/T	<i>CYP1A1</i>	0.311	0.315	0.894	0.98 (0.76-1.26)	0.869
rs4784165	16q12.1	G/T	<i>TOX3</i>	0.388	0.403	1.000	0.94 (0.74-1.19)	0.593
rs2059807	19p13.2	G/A	<i>INSR</i>	0.460	0.426	1.000	1.14 (0.91-1.44)	0.253
rs6022786	20q13.2	A/G	<i>SUMO1P1</i>	0.472	0.465	0.642	1.03 (0.82-1.29)	0.809

* p-value ≤0.05 indicates statistical significance; A/B stands for minor/major alleles on the control sample frequencies. HWE: Hardy-Weinberg equilibrium; MAF: minor allele frequency, OR: odds ratio, CI: confidence interval, SNP: single-nucleotide polymorphism

ethnic people. Our results also showed that rs705702 in the *RAB5B/SUOX* was associated with PCOS risk, while other loci were not found to be significantly associated with PCOS risk. The different genotype distributions might reflect differences in genetic background, and therefore gene variants might be associated with different relative risks in different populations. Although a previous study demonstrated that these SNPs were associated with PCOS in Han Chinese women, the current study showed that these SNPs were not involved in the pathogenesis in Xi'an Han Chinese women. These different results indicated that there is different genetic background between these SNPs and PCOS.

rs705702 is located at 12q13.2 between the *RAB5B* and *SUOX* genes. *RAB5B*, PCOS GWAS candidate, is a Rab-GTPase, also thought to be involved in endocytosis and receptor recycling and could, therefore, be a molecule interacting with the DENN domain (20,21,22) and has also been reported to involve PI3K, PKB, and MAPK/ERK components (23). *RAB5B* is a small GTPase that plays a role in early endosome formation and is required for the endocytic pathway that mediates the transport of clathrin-coated vesicles from the plasma membrane to the early endosome. *RAB5B* is a member of the RAS oncogene family and *SUOX*, sulfite oxidase, is a homodimeric protein enzyme localized to the intermembrane space of mitochondria, which catalyzes oxidation of sulfite to sulfate, the final reaction in the oxidative degradation of the sulfur amino acids cysteine and methionine. rs705702 was not associated with PCOS in the current study and was only nominally significant in previous European studies (13).

Shi et al (7) found that rs705702 in *RAB5B/SUOX* was associated with PCOS in the Han Chinese study and in our current study, we also showed that it was associated with PCOS in Xi'an Han Chinese people. As to other loci, in our study, we found no significant correlations with PCOS. However, in the GWAS study, it was reported that rs13405728 (*LHCGR*), rs3802457 (*C9orf3*), rs1894116 (*YAP1*), rs2272046 (*HMGA2*), rs4784165 (*TOX3*), rs2059807 (*INSR*), and rs6022786 (*SUMO1P1*) were associated with PCOS risk in Han China (7). In addition, rs13405728 was shown to have an association with PCOS in Hui Chinese people (12). rs3802457 was shown to be related to PCOS in a Dutch study (4). As to other loci, an association with PCOS risk has not been reported in studies from Europe. Therefore, the ultimate role of this variant in PCOS pathogenesis remains to be determined.

To conclude, our study has, for the first time, described an association between SNPs in *RAB5B* and PCOS risk in a group composed of Han individuals of Xi'an China. Large well-designed and population-based studies are warranted to confirm these findings which may well have implications for the etiology of PCOS.

Acknowledgments

This work is supported by the Shaanxi Provincial scientific and technological research projects S2015YFSF0310. We are grateful to all the patients and individuals in the study who made this work possible. We would also like to thank the clinicians and hospital staff who contributed to data collection for this study.

Table 4. Association between rs705702 and Polycystic ovary syndrome risk

SNP ID	Model	Genotype	Controls	Cases	OR (95% CI) ^a	OR (95% CI) ^b	p ^a	p ^b	
rs705702	Codominant	A/A	194 (64.9%)	159 (55.8%)	1	1	0.048	0.048	
		A/G	91 (30.4%)	103 (36.1%)	1.38 (0.97-1.96)	1.46 (1.01-2.12)			
		G/G	14 (4.7%)	23 (8.1%)	2.00 (1.00-4.02)	1.89 (0.91-3.96)			
	Dominant	A/A	194 (64.9%)	159 (55.8%)	1	1	0.025	0.018	
		A/G-G/G	105 (35.1%)	126 (44.2%)	1.46 (1.05-2.04)	1.52 (1.07-2.16)			
	Recessive	A/A-A/G	285 (95.3%)	262 (91.9%)	1	1	0.092	0.17	
		G/G	14 (4.7%)	23 (8.1%)	1.79 (0.90-3.55)	1.66 (0.80-3.42)			
	Over-dominant	A/A-G/G	208 (69.6%)	182 (63.9%)	1	1	0.14	0.079	
		A/G	91 (30.4%)	103 (36.1%)	1.29 (0.92-1.83)	1.38 (0.96-1.99)			
	Log-additive	---	---	---	---	1.40 (1.07-1.83)	1.42 (1.07-1.89)	0.014	0.014

p-value ≤0.05 indicates statistical significance;
OR: odd ratio; CI: confidence interval, SNP: single-nucleotide polymorphism
p^a: p-values were calculated from two-sided chi-square tests or Fisher's exact tests for either genotype distribution.
p^b: p-values were calculated by unconditional logistic regression adjusted for age & body mass index.

Ethics

Ethics Committee Approval: Second Affiliated Hospital, Xi'an Jiatong University during 2009 to 2013, Informed Consent: Written informed consent was obtained from all participants.
Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: Ming Liu, Design: Ying Sun, Tianbo Jin, Data Collection or Processing: Yi Yuan,

Analysis or Interpretation: Hua Yang, Tian Feng, Literature Search: Jingjie Li, Yongri Ouyang, Writing: Ying Sun.

Financial Disclosure: The authors declared that this study received no financial support.

References

- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004;89:2745-2749.
- Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. *Gynecol Endocrinol* 2010;26:281-296.
- Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. *Expert Rev Mol Med* 2008;10:3.
- Vink JM, Sadzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. *J Clin Endocrinol Metab* 2006;91:2100-2104. Epub 2005 Oct 11
- Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. *Nat Rev Genet* 2005;6:95-108.
- Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J, Liang X, Zhao X, Zhao J, Sun Y, Zhang B, Jiang H, Zhao D, Bian Y, Gao X, Geng L, Li Y, Zhu D, Sun X, Xu JE, Hao C, Ren CE, Zhang Y, Chen S, Zhang W, Yang A, Yan J, Li Y, Ma J, Zhao Y. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. *Nat Genet* 2011;43:55-59. Epub 2010 Dec 12
- Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, Zhang B, Liang X, Li T, Chen J, Shen J, Zhao J, You L, Gao X, Zhu D, Zhao X, Yan Y, Qin Y, Li W, Yan J, Wang Q, Zhao J, Geng L, Ma J, Zhao Y, He G, Zhang A, Zou S, Yang A, Liu J, Li W, Li B, Wan C, Qin Y, Shi J, Yang J, Jiang H, Xu JE, Qi X, Sun Y, Zhang Y, Hao C, Ju X, Zhao D, Ren CE, Li X, Zhang W, Zhang Y, Zhang J, Wu D, Zhang C, He L, Chen ZJ. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. *Nat Genet* 2012;44:1020-1025. Epub 2012 Aug 12
- Hashiramoto M, Osawa H, Ando M, Murakami A, Nishimiya T, Nakano M, Nishida W, Onuma H, Makino H. A nonsense mutation in the Arg345 of the insulin receptor gene in a Japanese type A insulin-resistant patient. *Endocr J* 2005;52:499-504.
- Feng C, Lv PP, Yu TT, Jin M, Shen JM, Wang X, Zhou F, Jiang SW. The association between polymorphism of INSR and polycystic ovary syndrome: a meta-analysis. *Int J Mol Sci* 2015;16:2403-2425.
- Bentov Y, Kenigsberg S, Casper RF. A novel luteinizing hormone/chorionic gonadotropin receptor mutation associated with amenorrhea, low oocyte yield, and recurrent pregnancy loss. *Fertil Steril* 2012;97:1165-1168. Epub 2012 Feb 25
- Wang P, Zhao H, Li T, Zhang W, Wu K, Li M, Bian Y, Liu H, Ning Y, Li G, Chen ZJ. Hypomethylation of the LH/choriogonadotropin receptor

- promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome. *Endocrinology* 2014;155:1445-1452. Epub 2014 Feb 14
12. Ha L, Shi Y, Zhao J, Li T, Chen ZJ. Association Study between Polycystic Ovarian Syndrome and the Susceptibility Genes Polymorphisms in Hui Chinese Women. *PLoS One* 2015;10:e0126505.
 13. Louwers YV, Stolk L, Uitterlinden AG, Laven JS. Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome. *J Clin Endocrinol Metab* 2013;98:2006-2012. Epub 2013 Oct 8
 14. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertil Steril* 2012;97:28-38. Epub 2011 Dec 6
 15. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. *Current Protocols in Human Genetics* 2009;2:2-12.
 16. Thomas RK, Baker AC, DeBiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhir R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liao LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. *Nat Genet* 2007;39:567. Epub 2007 Feb 11
 17. Bland JM, Altman DG. Statistics notes. The odds ratio. *BMJ* 2000;320:1468.
 18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263-265. Epub 2004 Aug 5
 19. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. *Cell Res* 2005;15:97-98.
 20. Stenmark H. Rab GTPases as coordinators of vesicle traffic. *Nat Rev Mol Cell Biol* 2009;10:513-525. Epub 2009 Jul 15
 21. Stenmark H, Olkkonen VM. The Rab GTPase family. *Genome Biol* 2001;2:REVIEWS3007. Epub 2001 Apr 27
 22. Chiariello M, Bruni CB, Bucci C. The small GTPases Rab5a, Rab5b and Rab5c are differentially phosphorylated in vitro. *FEBS Lett* 1999;453:20-24.
 23. Allaire PD, Marat AL, Dall'Armi C, Di Paolo G, McPherson PS, Ritter B. The Connecdenn DENN domain: a GEF for Rab35 mediating cargo-specific exit from early endosomes. *Mol Cell* 2010;37:370-382.